Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Depreciation and Depletion (2016 - 2025)

Voyager Therapeutics' Depreciation and Depletion history spans 11 years, with the latest figure at $1.1 million for Q4 2025.

  • For Q4 2025, Depreciation and Depletion rose 7.72% year-over-year to $1.1 million; the TTM value through Dec 2025 reached $4.1 million, down 13.34%, while the annual FY2025 figure was $4.1 million, 13.34% down from the prior year.
  • Depreciation and Depletion for Q4 2025 was $1.1 million at Voyager Therapeutics, up from $932000.0 in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $2.8 million in Q1 2022 and bottomed at $834000.0 in Q4 2022.
  • The 5-year median for Depreciation and Depletion is $1.2 million (2021), against an average of $1.2 million.
  • The largest annual shift saw Depreciation and Depletion soared 120.72% in 2022 before it plummeted 61.77% in 2023.
  • A 5-year view of Depreciation and Depletion shows it stood at $1.5 million in 2021, then plummeted by 43.72% to $834000.0 in 2022, then surged by 55.16% to $1.3 million in 2023, then dropped by 21.87% to $1.0 million in 2024, then rose by 7.72% to $1.1 million in 2025.
  • Per Business Quant, the three most recent readings for VYGR's Depreciation and Depletion are $1.1 million (Q4 2025), $932000.0 (Q3 2025), and $1.1 million (Q2 2025).